News|Articles|April 9, 2026

Meta-Analysis Supports Efficacy, Cost Savings of In-Home Vitiligo Therapy

Listen

0:00 / 0:00

Key Takeaways

Meta-analyzed RCTs showed home UVB was not inferior to clinic UVB for >50% repigmentation (OR 1.04) and >75% repigmentation (OR 1.26), albeit with wide CIs.
Evidence base was limited to Fitzpatrick III–V phototypes with 12–24 week follow-up, constraining generalizability and long-term durability inferences.
Home-based treatment produced numerically higher adherence (89.6% vs 83.7%), aligning with reduced travel burden and potential access expansion.
Adverse events were similar between settings for erythema and burning; perilesional hyperpigmentation in one home-UVB cohort highlighted the need for dosing protocols and patient training.
Annual in-office phototherapy costs were estimated at ~4× home panel acquisition, but lower irradiance and longer sessions mandate ongoing clinician monitoring and structured follow-up.

At-home phototherapy is more convenient than in-office care, and investigators found its one-time costs are also far less than the cost of care in a clinic.

A new meta-analysis has found that home-based phototherapy for vitiligo has similar efficacy to in-office phototherapy and suggests that at-home treatment may have positive impacts on patient adherence.

The study also found that in-home therapy did not increase the risk of adverse events. The report was published in the journal Photodermatology, Photoimmunology & Photomedicine.¹

Phototherapy with narrowband UVB is the cornerstone of vitiligo treatment, the authors explained. Yet, effective UVB phototherapy generally requires patients to travel to a health care provider’s office 2 to 3 times per week.

“In-office UVB therefore requires a significant time investment by patients and may not be accessible to those living far away from such clinics,” they wrote.

The development of portable, hand-held UVB devices has prompted more patients to consider in-home treatment. Previous research found that such home-based devices can be effective at treating the disease.² However, the investigators noted there is a limited amount of research on the safety and efficacy of home-based UVB.¹

They decided to conduct a meta-analysis to better understand the potential of in-home UVB. Searching medical databases, they identified 18 studies whose primary end point related to home-based vitiligo treatment. However, only 4 of the studies met the authors’ criteria for inclusion in the meta-analysis. Those trials included 148 patients who used in-home UVB phototherapy and 143 patients who used in-office phototherapy.

The studies in the meta-analysis used either 50% repigmentation or 75% repigmentation as their primary outcomes. The data showed that, by both benchmarks, home-based UVB was not inferior. The OR for greater than 50% repigmentation using in-home UVB was 1.04 (95% CI, 0.58-1.87). For greater than 75% repigmentation, the OR was 1.26 (95% CI, 0.65-2.42).

The investigators said the studies included in the analysis assessed efficacy among Fitzpatrick Type III to V skin phototypes only, and their follow-up duration lasted between 12 and 24 weeks.

In terms of adherence, the studies showed a slightly higher rate of adherence to home-based UVB compared with in-office therapy (89.6% vs 83.7%), although the difference was not statistically significant.

The most commonly reported adverse events within the trials were erythema and burning sensations. Patients treated at home had similar rates of erythema (OR, 1.74; 95% CI, 0.28-10.92) and burning (OR, 1.36; 95% CI, 0.16-11.71) to those of patients receiving in-office care. Other events, such as edema and blistering, were uncommon, the authors reported.

One study reported that 10 of 52 patients using home-based therapy experienced perilesional hyperpigmentation, while none of the 48 patients who had in-office UVB reported the same.³ That study concluded that better patient education was needed to avoid excessive UVB exposure.

From a cost perspective, the investigators found that the cost of 1 year of in-office care (including insurance reimbursements and patient out-of-pocket costs) was about 4 times the cost of purchasing full-sized panels for in-home use.¹ Handheld devices are even less expensive, they noticed.

However, that in-home UVB still requires careful consideration. The authors noted that differences between the irradiance of in-home and in-office devices mean that patients who use in-home therapy will likely need longer treatment sessions. They said regular follow-up and guidance from health care professionals is also necessary in order to ensure the patient follows an effective dosing plan.

Overall, though, the results of their meta-analysis support the use of home-based UVB (HBUVB) therapy.

“Being both affordable and convenient, HBUVB offers a crucial treatment option for individuals with vitiligo who might otherwise lack access to in-office treatment,” they concluded.

References

Xireaili F, Ha H, Liu ZF, et al. The effectiveness of home-based phototherapy in vitiligo: a systematic review and meta-analysis. Photodermatol Photoimmunol Photomed. 2026;42(2):e70079. doi:10.1111/phpp.70079
Tien Guan ST, Theng C, Chang A. Randomized, parallel group trial comparing home-based phototherapy with institution-based 308 excimer lamp for the treatment of focal vitiligo vulgaris. J Am Acad Dermatol. 2015;72(4):733-735. doi:10.1016/j.jaad.2014.12.026
Liu B, Sun Y, Song J, Wu Z. Home vs hospital narrowband UVB treatment by a hand-held unit for new-onset vitiligo: a pilot randomized controlled study. Photodermatol Photoimmunol Photomed. 2020;36(1):14-20. doi:10.1111/phpp.12495